Background: Lung cancer is the leading cause of cancer mortality worldwide. It is often diagnosed at an advanced stage when treatment is no longer possible. Early population-based screening may provide an opportunity for early diagnosis and reduce mortality rates.
Introduction
Lung cancer accounts for 26.8% of all cancer deaths making it the leading cause of cancer mortality worldwide. [1] Due to the asymptomatic nature of lung neoplasms, they are often diagnosed at an advanced stage when cure with the currently available therapies is unlikely. The survival rate from lung cancer has only slightly increased over the last 40 years, yet patients with early stage, localized nodules have a much higher 5-year survival rate as compared to those with later stage regional and metastasized cases (54.8% vs 27.4% vs 4.2%, respectively). [1] Therefore, early, effective population-based screening is a public health priority for increasing survival rates.
Conventional screening for lung neoplasms includes chest X-ray (CXR), sputum cytology, or no particular intervention or screening modality (standard care). Previous trials have shown that conventional screening methods are ineffective in detecting early lung cancer. [2] [3] [4] [5] [6] Low-dose computed tomography (LDCT) has emerged as a promising mass screening method for the early diagnosis of lung neoplasms. Several observational and randomized control trials (RCTs) since the 1990s have confirmed a high sensitivity for LDCT in early stage lung neoplasm detection. [7] [8] [9] [10] [11] [12] [13] Research suggests that LDCT results in overdiagnosis of lung cancer (a high false-positive rate), [14, 15] resulting in excess followup testing, invasive procedures, and patient anxiety. [16] [17] [18] Meta-analysis of clinical data is an increasingly common tool with the primary goal of obtaining a precise estimate of the overall effect of an intervention/screening technology. Early systematic reviews of LDCT [19] [20] [21] included single-arm prospective cohort studies and did not present the baseline findings of newer RCTs. Recent reviews [22] [23] [24] did not include meta-analysis of pooled data. The only found meta-analysis comparing LDCT to other screenings [25] reviewed the baseline data of 5 trials published at that time. In this article, we update the known metaanalysis with new published data from RCTs. Combining data from multiple studies allows us to compare its efficacy to conventional screening methods. Moreover, pooling the mortality data gives us a more precise estimate of LDCT screening efficacy in reducing death from lung cancer among high-risk tobacco-exposed subjects.
Methods
This meta-analysis was reported according to the PRISMA guidelines. The ethnic review was approved by the Affiliated Hospital of Bengbu Medical College.
Search strategy
We performed a literature search of Medline database (via PubMed) in November 31, 2017. The following search terms were used: "lung neoplasm" AND "mass screening" OR "early diagnosis" OR "computed tomography" OR "X-ray." We also hand-searched the reference lists from the eligible studies for additional relevant records. Duplicates were manually removed. The remaining studies underwent title and abstract screening and were classified as included, more information needed, or excluded based on our predefined exclusion criteria. Studies classified as included or more information required were subjected to full-text screening. Screening was performed independently by 2 authors (HL and YS). Differences in classification between reviewers were resolved by consensus.
Selection criteria
Studies were included if they: were RCTs providing lung cancer diagnosis and mortality rates, compared LDCT to any other type of screening, reported the outcomes for both intervention and control arms. All age groups were eligible for inclusion. In trials with multiple endpoints, mortality outcomes after the longest follow-up period were used. The following studies were excluded: conference abstracts/summaries, case reports/series, reviews, and commentaries/editorials. Non-English articles were also excluded.
Data extraction
Two authors (HL and YS) independently completed data extraction using the criteria above. Disagreements were resolved by consensus. The following data were extracted from each study: author, publication year, country, study size and duration, patient characteristics, screening modality, follow-up duration, and outcomes.
Outcomes
The assessed outcomes included lung cancer diagnosis and mortality rates. These outcomes were used to assess the benefits of LDCT compared to other screening methods. Validity and risk of bias assessments within the study and across studies were performed separately by 2 reviewers (HL and YS), with conflicts resolved by consensus. The assessment evaluated generalizability, sample size, and follow-up duration.
Statistical analysis
Statistical analyses were performed using OpenMetaAnalyst-0.1503 software (open-source), funded by Agency of Health care Research and Quality (AHRQ). A P-value of less than .05 was deemed statistically significant. Meta-analysis was performed to compare the outcomes of patients screened with LDCT versus other screening methods (CXR, sputum cytology, usual care with no screening). Results were reported as odds ratio (OR) and associated 95% confidence intervals (CIs). Heterogeneity was measured using the Q test and the I 2 statistic (with values of <25%, 25-50%, and 50-75% representing low, medium, and high heterogeneity). The DerSimonian-Laird randomeffects model was used if there was high heterogeneity between studies.
Results

Literature search results
The initial literature search retrieved 1858 records. After elimination of nonrelevant records, 15 full-text articles were reviewed. After application of all inclusion and exclusion criteria, 4 studies were finally included in this meta-analysis including 64,129 participants in total (Table 1) .
Characteristics of included studies
The U.S. National Lung Cancer Screening Trial (NLST) [15, 26] randomized 53,454 male and female participants to compare three annual LDCT screenings to three annual CXRs. It was conducted in 33 urban, academic tertiary care centers. Participants were former (less than 15 years since quitting) or current smokers with more than 30 pack-years and were followed for a median of 6.5 years. Overall, the NLST cohort was younger, better educated and more frequently former smokers than the general eligible US population, introducing the risk of the healthy-volunteer effect.
The Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays (DANTE) trial [27, 28] randomized 2472 male smokers (with a minimum of 20 pack-year smoking history) to receive 5 years of annual LDCT screening or usual care. All participants received a baseline physical examination and clinical interview, as well as a CXR and sputum cytology. This Italian trial was conducted in 2 community hospitals with an adherence rate of 95% over 5 rounds of screening. Generizability was inhibited by inclusion of only male subjects and the relatively small ample size.
The Danish Lung Cancer Screening Trial (DLCST) [29, 30] randomized 4104 men and woman who were current or former smokers (quit after the age of 50 years and within 10 years before trial enrollment) with ≥20 pack-years and were able to walk up 36 stairs without stopping. The DLCST was a single center trial [31] randomized 4099 men and women to compare annual (n = 1190) or biennial (1186) LDCT to no lung cancer screening (n = 1723). This single-center trial enrolled participants who were current or former (quit within 10 years of study enrollment) smokers. This study had a short median follow-up time of 4.4 years (at time of last published data) and more importantly differing follow-up periods among study arms (Table 2 ).
Meta-analysis outcomes
The random-effects model was the best fit for this analysis because the I 2 statistic was greater than 75%. The frequentist pairwise random effects meta-analysis on lung cancer incidence showed an OR of 1.86 (95% CI = 1.02-3.37), indicating people who underwent LDCT screening had a higher incidence of diagnosed lung cancer. The baseline 95% CIs demonstrated statistically significant differences between the screening modalities. As the MILD trial had different follow-up periods among the LDCT and control groups, we also performed the analysis excluding the MILD trial. The results of the pooled data, excluding the MILD trial, displayed an OR of 1.95 (95% CI = 0.78-4.90). This indicates no significant difference between the screening modalities due to the larger CI including the null hypothesis value (Figs. 1 and 2) .
The random effects meta-analysis on lung cancer mortality showed an OR of 1.13 (95% CI = 0.78-1.64). The OR after the exclusion of the MILD trial was OR = 1.02 (95% CI = 0.66-1.58). In both cases, the CIs render the ORs insignificant and demonstrate mortality due to lung cancer is approximately the same in both LDCT and control groups (Figs. 3 and 4) .
Discussion
The increase in lung cancer detection among LDCT study arms as compared to other screening methods indicates LDCT may be an effective mass screening tool for high risk individuals. This may be especially important when considering diagnosed stage I cancers have a higher survival rate than later lung cancers stages. A decease in lung cancer mortality with LDCT screening continues to be unfounded in the literature. This may indicate that while the LDCT screening is more effective than other screening modalities for early Table 1 PRISMA: LDCT versus other screening methods: meta-analysis flow diagram.
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Wang et al. Medicine (2018) 97:27 www.md-journal.com lung cancer diagnosis, it does not translate into a meaningful reduction in mortality at the population level. This may be partially attributed to biases, common to screening programs, such as lead time, length time, and overdiagnosis bias. Moreover, the 2 smaller trials (DLCST and NLST) may have canceled out the positive screening effects of the NLST study. These smaller studies included a younger population with less pack-years than the higher-risk NLST participants. While the NLST study may be more applicable to the US medical context and was the only study large enough to detect a difference among study arms, the efficacy of a population-based screening program will depend greatly on implementation factors. The NLST was conducted among a population with a higher risk than the European trials and the general eligible US population. Moreover, it was largely conducted at academic centers with specialty cancer centers and therefore, calls into question the generalizability to a greater population in the community care setting. The NLST was a head-to-head trial comparing LDCT against CXR where the European trials include a placebo-like group (community care) perhaps biasing the overdiagnosis rate in the NLST study leading to increased cost, risk and anxiety. Population-based screening among patients who would have been eligible, according to NLST inclusion criteria, is unlikely to be cost-effective with such a small decrease in mortality compared to the standard care. The inclusion criteria for a mass-screening program will have to be determined and if restricted to those only at the highest risk, may be perceived as inequitable among health consumers at risk but ineligible due to the current risk standards.
Limitations
This meta-analysis included a small number of studies and the trials included for analysis were under-powered at an individual level. The high level of heterogeneity between studies is a limitation to the ability to extrapolate results from this meta-analysis to the general Table 2 Characteristics of included studies.
Study ID Population Country
Follow-up period They also varied in size; the largest study randomized more than 50,000 participants while the other three combined randomized fewer than 10,000. Also the trials differed in their follow-up periods even among study arms as in the MILD trial. In addition, the smaller trials demonstrated heterogeneous study methods, selection criteria, and screening modalities. The study outcomes may also vary due to location, participant demographics, and differences in healthcare systems between the international locations of the trials. At the review-level, there is the risk of incomplete retrieval of unidentified research or reporting bias.
Implications of key findings
Due to the lack of a significant difference in mortality after LDCT screening in individuals at high risk for lung cancer, patients and clinicians must weigh the individual benefits versus the overall risks of LDCT testing including radiation exposure, high falsepositive rates, and costs of follow-up testing and treatments. [32] Policy makers will need further research, as well as developments in the computed tomography technology [33] [34] [35] to develop recommendations on the implementation of mass screening by LDCT both in higher-risk and lower-risk individuals. 
Author contributions
